Medications that mimic GLP-1 (like semaglutide and tirzepatide) are FDA-approved for: Type 2 diabetes management (Ozempic) Chronic weight management (Wegovy, Zepbound, and Mounjaro) These drugs help reduce appetite, slow digestion, and improve metabolic efficiencyall of which support gradual, sustainable weight loss
For a minority of patients, persistent nausea continues beyond the initial adaptation period and may not fully resolve even after several months of treatment
While neither inositol nor metformin typically causes hypoglycemia when used alone in non-diabetic individuals, patients should be aware of symptoms such as shakiness, sweating, confusion, or rapid heartbeat
In fact, Ferreira said, lifestyle modification is really important for all patients
Whether tirzepatide increases metabolism directly, or simply creates the conditions for metabolic improvement through weight loss and body composition changes, is a question that researchers continue to investigate